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Gemfibrozil, a lipid-lowering drug, inhibited cyto-
kine-induced production of NO and the expression of
inducible nitric-oxide synthase (iNOS) in human
U373MG astroglial cells and primary astrocytes. Similar
to gemfibrozil, clofibrate, another fibrate drug, also in-
hibited the expression of iNOS. Inhibition of human
iNOS promoter-driven luciferase activity by gemfibrozil
in cytokine-stimulated U373MG astroglial cells suggests
that this compound inhibits the transcription of iNOS.
Since gemfibrozil is known to activate peroxisome pro-
liferator-activated receptor- (PPAR-), we investigated
the role of PPAR- in gemfibrozil-mediated inhibition of
iNOS. Gemfibrozil induced peroxisome proliferator-re-
sponsive element (PPRE)-dependent luciferase activity,
which was inhibited by the expression of hPPAR-, the
dominant-negative mutant of human PPAR-. However,
hPPAR-was unable to abrogate gemfibrozil-mediated
inhibition of iNOS suggesting that gemfibrozil inhibits
iNOS independent of PPAR-. The human iNOS pro-
moter contains consensus sequences for the binding of
transcription factors, including interferon- (IFN-)
regulatory factor-1 (IRF-1) binding to interferon-stimu-
lated responsive element (ISRE), signal transducer and
activator of transcription (STAT) binding to -activation
site (GAS), nuclear factor-B (NF-B), activator pro-
tein-1 (AP-1), and CCAAT/enhancer-binding protein 
(C/EBP); therefore, we investigated the effect of gemfi-
brozil on the activation of these transcription factors.
The combination of interleukin (IL)-1 and IFN- in-
duced the activation of NF-B, AP-1, C/EBP, and GAS
but not that of ISRE, suggesting that IRF-1 may not be
involved in cytokine-induced expression of iNOS in hu-
man astrocytes. Interestingly, gemfibrozil strongly in-
hibited the activation of NF-B, AP-1, and C/EBP but
not that of GAS in cytokine-stimulated astroglial cells.
These results suggest that gemfibrozil inhibits the in-
duction of iNOS probably by inhibiting the activation of
NF-B, AP-1, and C/EBP and that gemfibrozil, a pre-
scribed drug for humans, may further find its therapeu-
tic use in neuroinflammatory diseases.
It is now increasingly clear that glial cells (astrocytes and
microglia) in the central nervous system (CNS)1 induce the
expression of inducible nitric-oxide synthase (iNOS) and the
production of NO in response to proinflammatory cytokines,
including interleukin-1 (IL-1), tumor necrosis factor- (TNF-
), and interferon- (IFN-) (1–4). Although the NO produced
by iNOS has bactericidal and tumoricidal properties, it also
plays an important role in pathophysiologies of inflammatory
neurological diseases including demyelinating disorders (e.g.
multiple sclerosis, experimental allergic encephalopathy), neu-
rodegenerative disorder like Alzheimer’s disease, and in ische-
mic and traumatic brain injuries associated with the activation
of glial cells and the production of proinflammatory cytokines
(5–8). NO derived from activated glial cells is assumed to
contribute to oligodendrocyte degeneration in demyelinating
diseases and neuronal death during ischemia and trauma (5,
6). Therefore, characterization of intracellular pathways re-
quired to transduce the signal from the cell surface to the
nucleus for the induction of iNOS is an active area of investi-
gation, since compounds capable of antagonizing signaling
steps for the induction of iNOS may have therapeutic effect in
NO-mediated pathophysiological conditions.
Peroxisome proliferator-activated receptors (PPARs), mem-
bers of the nuclear hormone receptor superfamily, have been
implicated in a variety of human diseases (9). Three isotypes
have been described to date, PPAR-, PPAR-, and PPAR- (9).
Activation of PPAR- mainly leads to the induction of a variety
of genes such as those coding for the enzymes for - and
-oxidation of fatty acids (10). Gemfibrozil, an activator of
PPAR-, has been often prescribed in patients to lower the
level of triglycerides (11, 12). This drug decreases the risk of
coronary heart disease by increasing the level of high density
lipoprotein cholesterol and decreasing the level of low density
lipoprotein cholesterol (11, 12). Activation of PPAR- is also
capable of modifying the stress response by activation of heat
shock factor 1 (HSF-1) and induction of HSP70 (13, 14). Re-
cently it has been shown that activation of HSP70 inhibits the
expression of iNOS in astrocytes (15), suggesting that the ex-
pression of iNOS may also be regulated by activators of
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PPAR-. Therefore, we investigated the effect of gemfibrozil on
the expression of iNOS in cytokine-stimulated human U373MG
astroglial cells and primary astrocytes. In the current work, we
present evidence that gemfibrozil markedly inhibited the ex-
pression of iNOS and the production of NO in human astro-
cytes independent of PPAR-. In addition, reporter gene assays
reveal that gemfibrozil specifically inhibited cytokine-induced
activation of NF-B, AP-1, and C/EBP but not that of GAS.
These results raise the possibility that gemfibrozil, a common
lipid-lowering drug, may be of therapeutic value in human
neuroinflammatory diseases.
MATERIALS AND METHODS
Reagents—Fetal bovine serum and DMEM/F-12 were from Invitro-
gen. Human recombinant IFN-, IL-1, and TNF- were purchased
from R & D Systems. L-NG-Monomethylarginine (L-NMA) and D-NG-
monomethylarginine (D-NMA) were obtained from Biomol. Gemfibrozil
and clofibrate were obtained from Sigma. Antibodies against human
macrophage iNOS were obtained from Calbiochem. 125I-Labeled protein
A and [-32P]dCTP (3000 Ci/mmol) were purchased from PerkinElmer
Life Sciences. Peroxisome proliferator-responsive element (PPRE)-de-
pendent reporter construct (tk-PPREx3-Luc) and dominant-negative
mutant of CCAAT/enhancer-binding protein  (C/EBP) were kindly
provided by Dr. Ronald M. Evans of The Salk Institute and Dr. Steve
Smale of the University of California at Los Angeles, respectively.
Preparation of Human Astrocytes—Human CNS tissue was obtained
from the Human Embryology Laboratory, University of Washington,
Seattle. The CNS tissue from each specimen was processed separately
and independently, as were subsequent cell cultures; there was no
pooling of CNS tissue from distinct specimens. All the experimental
protocols were reviewed and approved by the Institutional Review
Board (IRB number 224-01-FB) of the University of Nebraska Medical
Center. These cells were grown in a serum-free, defined medium (B16)
enriched with 5 ng of basic fibroblast growth factor per ml for optimal
growth of astrocytes and for the suppression of fibroblast growth (16).
By immunofluorescence assay, these cultures homogeneously expressed
glial fibrillary acidic protein (GFAP). Cells were trypsinized, subcul-
tured, and stimulated with cytokines in serum-free DMEM/F-12 me-
dium to induce the production of NO. The human U373MG astrocytoma
cell line, purchased from the American Type Culture Collection (ATCC),
was also maintained and stimulated under similar conditions.
Assay for NO Synthesis—Synthesis of NO was determined by assay
of culture supernatant for nitrite, a stable reaction product of NO with
molecular oxygen, using Griess reagent (1–4). Briefly, 400 l of culture
supernatant was allowed to react with 200 l of Griess reagent and
incubated at room temperature for 15 min. The optical density of the
assay samples was measured spectrophotometrically at 570 nm. Fresh
culture medium served as the blank in all experiments. Nitrite concen-
trations were calculated from a standard curve derived from the reac-
tion of NaNO2 in the assay. Protein was measured by the procedure of
Bradford (17).
Immunoblot Analysis for iNOS—Immunoblot analysis for iNOS was
carried out as described earlier (2–4). Briefly, cells were detached by
scraping, washed with Hanks’ buffer, and homogenized in 50 mM Tris-
HCl (pH 7.4) containing protease inhibitors (1 mM phenylmethylsulfo-
nyl fluoride, 5 g/ml aprotinin, 5 g/ml antipain, 5 g/ml pepstatin A,
and 5 g/ml leupeptin). After electrophoresis the proteins were trans-
ferred onto a nitrocellulose membrane, and the iNOS band was visual-
ized by immunoblotting with antibodies against human iNOS and 125I-
labeled protein A (2–4).
RNA Isolation and Northern Blot Analysis—Cells were taken out of
the culture dishes directly by adding Ultraspec-II RNA reagent (Biotecx
Laboratories, Inc.), and total RNA was isolated using Ultraspec-II RNA
reagent (Biotecx Laboratories Inc.) according to the manufacturer’s
protocol. For Northern blot analyses, 20 g of total RNA was electro-
phoresed on 1.2% denaturing formaldehyde-agarose gels, electrotrans-
ferred to Hybond-Nylon Membrane (Amersham Biosciences) and hy-
bridized at 68 °C with 32P-labeled cDNA probe using Express Hyb
hybridization solution (Clontech) as described by the manufacturer.
The cDNA probe was made by polymerase chain reaction amplification
using two primers (forward primer, 5-CTC CTT CAA AGA GGC AAA
AAT A-3; reverse primer, 5-CAC TTC CTC CAG GAT GTT GT-3)
(2–4, 18). After hybridization filters were washed two or three times in
solution I (2 SSC, 0.05% SDS) for 1 h at room temperature followed by
solution II (0.1 SSC, 0.1% SDS) at 50 °C for another hour. The mem-
branes were then dried and exposed to x-ray films (Eastman Kodak
Co.). The same amount of RNA was hybridized with probe for glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH).
Assay of iNOS Promoter-driven Reporter Activity—Construction of
phiNOS(7.2)Luc, the 7.2-kb human iNOS promoter-luciferase con-
struct, has been described previously (19). Cells plated at 50–60%
confluence in six-well plates were cotransfected with 1 g of
phiNOS(7.2)Luc and 50 ng of pRL-TK (a plasmid encoding Renilla
luciferase, used as transfection efficiency control; Promega) by Lipo-
fectAMINE Plus (Invitrogen) following manufacturer’s protocol (3, 4).
Twenty-four h after transfection, cells were treated with different stim-
uli for 12 h. Firefly and Renilla luciferase activities were obtained by
analyzing total cell extract according to standard instructions provided
in the Dual Luciferase Kit (Promega) in a TD-20/20 Luminometer
(Turner Designs). Relative luciferase activity of cell extracts was typi-
cally represented as the ratio of firefly luciferase value/Renilla lucifer-
ase value  103.
Assay of Transcriptional Activities of Different Proinflammatory
Transcription Factors—Cells plated at 50–60% confluence in six-well
plates were cotransfected with 1 g of either pNF-B-Luc (NF-B-de-
pendent reporter construct), pAP-1-Luc (AP-1-dependent reporter con-
struct), pC/EBP-Luc (C/EBP-dependent reporter construct), pGAS-
Luc (GAS-dependent reporter construct), or pISRE-Luc (ISRE-
dependent reporter construct) and 50 ng of pRL-TK using
LipofectAMINE Plus. Construction of pC/EBP-Luc has been described
earlier (4). This C/EBP-sensitive promoter contains four consensus
C/EBP-binding sites. Other reporter constructs (pNF-B-Luc, pAP-1-
Luc, pGAS-Luc, and pISRE-Luc) were obtained from Stratagene. After
24 h of transfection, cells were treated with different stimuli for 6 h.
Firefly and Renilla luciferase activities were obtained as described
above.
Statistics—Statistical comparisons were made using one-way analy-
sis of variance followed by Student’s t test.
RESULTS
Gemfibrozil Inhibits the Expression of iNOS in Cytokine-
stimulated Human U373MG Astroglial Cells—Cells were cul-
tured in serum-free media in the presence of IL-1 and IFN-.
It is evident from Table I that IL-1 and IFN- alone were poor
inducers of NO production. However, marked induction of NO
production was observed by the combination of IL-1 and
IFN-. This combination of cytokines was used to induce the
production of NO in subsequent studies. The inhibition of cy-
tokine-induced production of NO by arginase (an enzyme that
degrades the substrate, L-arginine, of NOS) and L-NMA (a
competitive inhibitor of NOS) but not by D-NMA (a negative
control of L-NMA) suggests that the combination of IL-1 and
IFN- induces the production of NO in U373MG astroglial cells
through NOS-mediated arginine metabolism (Table I). Next we
examined the effect of gemfibrozil, an activator of PPAR- (20),
on the cytokine-induced nitrite production in U373MG glial
cells. Gemfibrozil itself was neither stimulatory nor much in-
TABLE I
Induction of NO production in human U373MG astroglial cells
U373MG glial cells preincubated in serum-free DMEM/F-12 for 1 h
with arginase, L-NMA or D-NMA received the combination of IL-1 and
IFN-. After 24 h of incubation, nitrite concentrations in the superna-
tants were measured as described under “Materials and Methods.”
Data are expressed as the mean  S.D. of three different experiments.
The concentrations of different compounds were as follows: IL-1, 10
ng/ml; IFN-, 10 units/ml; arginase, 100 units/ml; L-NMA, 0.1 mM;
D-NMA, 0.1 mM; gemfibrozil, 200 M.
Treatments Nitrite production
g/mg protein/24 h
Control 6.2  0.8
IL-1 only 18.6  1.9
IFN- only 15.9  0.9
IL-1  IFN- 196.3  26.6
IL-1  IFN-  arginase 21.2  1.8a
IL-1  IFN-  L-NMA 19.1  2.1a
IL-1  IFN-  D-NMA 194.7  21.3
Gemfibrozil only 5.9  1.1
IL-1  IFN-  gemfibrozil 20.8  2.8a
a p  0.001 versus IL-1  IFN-.
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hibitory to NO production in control cells. However, gemfibro-
zil, when added 2 h before the addition of cytokines, markedly
inhibited cytokine-induced production of NO (Table I).
To determine whether inhibition of cytokine-induced NO
production by gemfibrozil was simply due to delayed induction,
we measured NO concentrations in cytokine-stimulated cul-
tures maintained up to 48 h. When cells were stimulated in the
absence of gemfibrozil, NO was detected in culture superna-
tants after 8 h and increased progressively thereafter for 48 h,
the duration of the experiment (Fig. 1). However, when 200 M
gemfibrozil was added 2 h before the addition of the combina-
tion of IL-1 and IFN-, production of NO was significantly
inhibited (Fig. 1). In our studies, maximal suppression of NO
production was observed when gemfibrozil was added 2 h be-
fore the addition of cytokines (data not shown). When gemfi-
brozil was added after the addition of cytokines, the extent of
inhibition progressively decreased (data not shown). It is evi-
dent from Fig. 2A that gemfibrozil dose-dependently inhibited
cytokine-induced production of NO. Although at 50 M concen-
tration, gemfibrozil was not a potent inhibitor of cytokine-
induced NO production, it inhibited the induction of NO pro-
duction by more than 80% at 200 M concentration. To
understand the mechanism of inhibition, we examined the
effect of gemfibrozil on protein and mRNA level of iNOS in
cytokine-stimulated cells. Consistent with the effect of gemfi-
brozil on cytokine-induced production of NO, gemfibrozil dose-
dependently inhibited cytokine-induced expression of iNOS
protein (Fig. 2B) and mRNA (Fig. 2C).
Next we investigated the possibility whether gemfibrozil in-
hibited cytokine-induced expression of iNOS mRNA by de-
creasing the stability of iNOS mRNA. Human U373MG astro-
glial cells were stimulated with the combination of IL-1 and
IFN- under serum-free condition. After 6 h of stimulation,
cells were treated with actinomycin D (an inhibitor of RNA
synthesis) in the presence or absence of 200 M of gemfibrozil.
At different h of treatment with actinomycin D, the level of
iNOS mRNA was analyzed by Northern blot. It is apparent
from figure 3, A and B, that the relative rate of degradation of
iNOS mRNA (iNOS/GAPDH) in the presence or absence of
gemfibrozil at different time periods remained almost same
suggesting that gemfibrozil-mediated inhibition of iNOS
mRNA is not due to any alteration of the stability of iNOS
mRNA.
Inhibition of Cytokine-induced Expression of iNOS by Clofi-
brate in Human U373MG Astroglial Cells—To investigate
whether other fibrate drugs are also capable of inhibiting cy-
tokine-induced production of NO and expression of iNOS in
astrocytes, we examined the effect of clofibrate. Clofibrate is
also a hypolipidemic drug that activates PPAR- and induces
proliferation of peroxisomes in rats and mice (9, 20, 21). Similar
to gemfibrozil, clofibrate itself was neither stimulatory nor
much inhibitory to NO production; however, it dose-depend-
ently inhibited the production of NO (Fig. 4A) and the expres-
sion of iNOS protein (Fig. 4B) in cytokine-stimulated U373MG
astroglial cells. These studies suggest that fibrate drugs, in
general, are inhibitory to cytokine-induced expression of iNOS
in human astroglial cells.
Inhibition of Cytokine-induced Production of NO by Gemfi-
brozil in Human Primary Astrocytes—Human primary astro-
cytes have been shown to induce the expression of iNOS in the
presence of different proinflammatory cytokines (22–24). Since
gemfibrozil potently inhibited the expression of iNOS in human
U373MG astroglial cells, we examined the effect of gemfibrozil
on cytokine-induced expression of iNOS in human primary
astrocytes. Different cytokines alone were poor inducers of NO
production (Table II). However, the combination of IL-1 and
IFN- markedly induced the production of NO. The addition of
TNF- to the combination of IL-1 and IFN- did not further
increase the production of NO (Table II). Although gemfibrozil
itself had no effect on NO production in control cells, preincu-
bation of human primary astrocytes with 200 M of gemfibrozil
FIG. 1. Time course of cytokine-induced NO production and its
suppression by gemfibrozil in human U373MG astroglial cells.
Cells preincubated with 200 M gemfibrozil for 2 h in serum-free
DMEM/F-12 received the combination of IL-1 (10 ng/ml) and IFN- (10
units/ml). At different hours of stimulation, the concentration of nitrite
was measured in supernatants using the “Griess reagent” as described
under “Materials and Methods.” Data are expressed as the mean of two
separate experiments.
FIG. 2. Gemfibrozil dose-dependently inhibits the expression
of iNOS in cytokine-stimulated human U373MG astroglial cells.
Cells preincubated with different concentrations of gemfibrozil for 2 h
in serum-free DMEM/F-12 received the combination of IL-1 (10 ng/ml)
and IFN- (10 units/ml). A, after 24 h of stimulation, the concentration
of nitrite was measured in the supernatants. Data are mean  S.D. of
three different experiments. a, p  0.001 versus control; b, p  0.005
versus IL-1IFN-; c, p  0.001 versus IL-1IFN-. B, cell homoge-
nates were immunoblotted with antibodies against mouse macrophage
iNOS as described under “Materials and Methods.” C, after 6 h of
stimulation, total RNA was isolated, and Northern blot analysis for
iNOS mRNA was carried out as described under “Materials and
Methods.”
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for 2 h markedly inhibited cytokine-induced production of NO
(Table II).
Gemfibrozil Inhibits Human iNOS Promoter-driven Lucifer-
ase Activity in Cytokine-stimulated Human U373MG Astroglial
Cells—To understand the effect of gemfibrozil on the transcrip-
tion of iNOS gene, U373MG glial cells were transfected with
phiNOS(7.2)Luc, a construct containing the human iNOS pro-
moter fused to the luciferase gene (19), and activation of this
promoter was measured after stimulating the cells with cyto-
kines in the presence or absence of gemfibrozil. The combina-
tion of IL-1 and IFN- induced iNOS promoter-driven lucif-
erase activity by about 3.9-fold (Fig. 5). Consistent with the
effect of gemfibrozil on the expression of iNOS, gemfibrozil
itself had no effect on iNOS promoter-driven luciferase activity
but it dose-dependently inhibited iNOS promoter-driven lucif-
erase activity in cytokine-stimulated cells (Fig. 5), suggesting
that gemfibrozil inhibits cytokine-induced production of NO
and the expression of iNOS mRNA by inhibiting the activation
of iNOS promoter.
Role of PPAR- in Gemfibrozil-mediated Inhibition of iNOS
in Human U373MG Astroglial Cells—Since gemfibrozil is a
known activator of PPAR- (9, 20, 21), a member of the nuclear
hormone receptor superfamily, we examined whether gemfi-
brozil inhibited the induction of iNOS through the activation of
PPAR-. PPARs bind to a consensus sequence known as PPRE
(9). Therefore, to study the activation of PPAR, cells were
transfected with tk-PPREx3-Luc, a PPRE-dependent luciferase
construct, and luciferase activity was measured. As shown in
Fig. 6A, gemfibrozil alone was able to induce PPRE-dependent
luciferase activity in a dose-dependent manner and the maxi-
mum induction (4-fold) was observed at 100 M or higher
concentration of gemfibrozil. In contrast, the combination of
IL-1 and IFN- capable of inducing iNOS inhibited PPRE-de-
pendent luciferase activity (Fig. 6A). However, gemfibrozil
treatment blocked the inhibitory effect of cytokines on the
activation of PPRE and stimulated PPRE-dependent luciferase
activity over basal level even in the presence of cytokines (Fig.
6A). To analyze the role of PPAR- in gemfibrozil-induced
activation of PPRE, we used hPPAR-, the dominant-nega-
tive mutant of human PPAR- (25). Marked abrogation (p 
0.001) of gemfibrozil-induced activation of PPRE (Fig. 6B) by
the expression of hPPAR- but not that of the empty vector
suggests that gemfibrozil induced PPRE-dependent reporter
activity through the activation of PPAR- in human astroglial
cells.
Next we examined whether hPPAR- can block the inhib-
itory effect of gemfibrozil on the induction of iNOS. Cells were
cotransfected with phiNOS(7.2)Luc, hPPAR-, and pRL-TK
(a plasmid encoding Renilla luciferase, used as transfection
efficiency control). After 24 h of transfection, cells were incu-
bated with gemfibrozil for 2 h followed by stimulation with
cytokines. Consistent, to the inhibitory effect of gemfibrozil on
FIG. 3. Effect of gemfibrozil on the stability of iNOS mRNA in
human U373MG astroglial cells. Cells were stimulated with the
combination of IL-1 (10 ng/ml) and IFN- (10 units/ml) under serum-
free condition. After 6 h of stimulation by cytokines, cells were treated
with 3 g/ml actinomycin D in the presence or absence of gemfibrozil,
and cells were analyzed for iNOS RNA by Northern blot (A) at different
hours of treatment. B, the relative level of iNOS mRNA (iNOS/GAPDH)
at different hours of treatment was determined after densitometric
scanning of iNOS and GAPDH bands by a Fluor Chem 8800 Imaging
System (Alpha Innotech Corp.). The data are expressed as the average
of two separate experiments.
FIG. 4. Clofibrate dose-dependently inhibits the expression of
iNOS in cytokine-stimulated human U373MG astroglial cells.
Cells preincubated with different concentrations of clofibrate for 2 h in
serum-free DMEM/F-12 received the combination of IL-1 (10 ng/ml)
and IFN- (10 units/ml). A, after 24 h of stimulation, the concentration
of nitrite was measured in the supernatants. Data are mean  S.D. of
three different experiments. a, p  0.001 versus control; b, p  0.005
versus IL-1  IFN-; c, p  0.001 versus IL-1  IFN-. B, cell
homogenates were immunoblotted with antibodies against mouse
macrophage iNOS.
TABLE II
Gemfibrozil inhibits the induction of NO production in human
primary astrocytes
Human primary astrocytes preincubated in serum-free DMEM/F-12
for 2 h with 200 M gemfibrozil, received IL-1, IFN-, and TNF- alone
or in different combinations. After 24 h of incubation, nitrite concen-
trations in the supernatants. Data are expressed as the mean  S.D. of
three different experiments. The concentrations of different cytokines
were as follows: IL-1, 10 ng/ml; IFN-, 10 units/ml; TNF-, 10 ng/ml.
Treatments Nitrite production
g/mg protein/24 h
Control 5.3  0.7
IL-1 24.5  2.5
IFN- 6.1  0.7
TNF- 5.8  0.8
Gemfibrozil 5.1  0.6
IL-1  IFN- 215.3  22.3
IL-1  IFN-  TNF- 219.2  28.5
IL-1  IFN-  gemfibrozil 24.8  2.8a
IL-1  IFN-  TNF-  gemfibrozil 25.7  3.1b
a p  0.001 versus IL-1  IFN-.
b p  0.001 versus IL-1  IFN-  TNF-.
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the activation of iNOS promoter (Fig. 5), this drug inhibited
iNOS promoter-driven luciferase activity in empty vector-
transfected cells (Fig. 7). However, despite the ability of hP-
PAR- to block gemfibrozil-mediated activation of PPRE (Fig.
6B), the expression of hPPAR- did not block the inhibitory
effect of gemfibrozil on iNOS promoter-driven luciferase activ-
ity in cytokine-stimulated cells (Fig. 7). These results suggest
that PPAR- is not involved in gemfibrozil-mediated inhibition
of iNOS in human astroglial cells.
Effect of Gemfibrozil on the Activation of Proinflammatory
Transcription Factors in Human U373MG Astroglial Cells—
Different proinflammatory transcription factors are known to
be involved in the transcription of iNOS (2–4, 26–30). Analysis
of human iNOS promoter shows that it has consensus se-
quences for binding of several transcription factors such as
NF-B, AP-1, C/EBP, IRF-1 binding to ISRE, and STAT bind-
ing to GAS (29–31). Although several reports have established
the involvement of NF-B, AP-1, and STAT in the induction of
iNOS in human cells (29, 32, 33), the role of C/EBP in the
induction of human iNOS has not been established. Overex-
pression of dominant-negative molecules provides an effective
tool with which to investigate the in vivo functions of different
transcription factors and signaling molecules. Therefore, we
used the dominant-negative mutant of C/EBP (C/EBP) (34)
to inhibit the activation of C/EBP. It is apparent from Fig. 8
that the expression of C/EBP but not that of the empty
vector inhibited iNOS promoter-driven luciferase activity sig-
nificantly (p  0.005) in cytokine-stimulated human U373MG
astroglial cells, suggesting the involvement of C/EBP in the
induction of iNOS in human astroglial cells.
Since gemfibrozil inhibited cytokine-induced activation of
human iNOS promoter (Fig. 5), we decided to investigate the
effect of gemfibrozil on the activation of these proinflammatory
transcription factors in cytokine-stimulated human U373MG
astroglial cells. Activation of these transcription factors was
monitored by transcriptional activity using the expression of
luciferase from respective reporter constructs. It is evident
FIG. 5. Gemfibrozil inhibits human iNOS promoter-derived lu-
ciferase activity in cytokine-stimulated human U373MG astro-
glial cells. Cells plated at 50–60% confluence in six-well plates were
cotransfected with 1 g of phiNOS(7.2)Luc (a construct containing the
human iNOS promoter fused to the luciferase gene) and 50 ng of
pRL-TK (a plasmid encoding Renilla luciferase, used as a transfection
efficiency control) using the LipofectAMINE Plus (Invitrogen). Twenty-
four hours after transfection, cells received different concentrations of
gemfibrozil. After 2 h of incubation, cells were stimulated with the
combination of IL-1 (10 ng/ml) and IFN- (10 units/ml) for 12 h under
serum-free condition. Firefly (ff-Luc) and Renilla (r-Luc) luciferase ac-
tivities were obtained by analyzing the total cell extract as described
under “Materials and Methods.” Data are mean  S.D. of three differ-
ent experiments. a, p  0.001 versus control; b, p  0.05 versus IL-1 
IFN-; c, p  0.001 versus IL-1  IFN-.
FIG. 6. The dominant-negative mutant of human PPAR-
(hPPAR-) inhibits gemfibrozil-induced PPRE-dependent lu-
ciferase activity in human U373MG astroglial cells. A, cells plated
at 50–60% confluence in six-well plates were cotransfected with 1 g of
tk-PPREx3-Luc, a PPRE-dependent luciferase reporter construct, and
50 ng of pRL-TK using LipofectAMINE Plus. Twenty-four hours after
transfection, cells were treated with different concentrations of gemfi-
brozil and/or the combination of IL-1 (10 ng/ml) and IFN- (10 units/
ml). After 6 h of incubation, firefly (ff-Luc) and Renilla (r-Luc) luciferase
activities were assayed. Data are mean  S.D. of three different exper-
iments. *, p  0.001 versus 200 M gemfibrozil. B, cells were cotrans-
fected with 0.5 g of either hPPAR- or an empty vector and 1 g of
tk-PPREx3-Luc. All transfections also included 50 ng/g of pRL-TK.
Twenty-four hours after transfection, cells were treated with different
concentrations of gemfibrozil. After 6 h of incubation, firefly (ff-Luc) and
Renilla (r-Luc) luciferase activities were assayed. Data are mean S.D.
of three different experiments. a, p  0.001 versus 100 M gemfibrozil;
b, p  0.001 versus 200 M gemfibrozil.
FIG. 7. hPPAR- does not block gemfibrozil-mediated inhibi-
tion of iNOS promoter activation in cytokine-stimulated human
U373MG astroglial cells. Cells were cotransfected with 0.5 g of
either hPPAR- or an empty vector, 0.5 g of phiNOS(7.2)Luc, and 50
ng of pRL-TK. Twenty-four hours after transfection, cells were incu-
bated with gemfibrozil for 2 h followed by stimulation with the combi-
nation of IL-1 and IFN-. After 12 h of incubation, firefly (ff-Luc) and
Renilla (r-Luc) luciferase activities were assayed. Data are mean S.D.
of three different experiments.
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from Fig. 9, A–D, that the combination of IL-1 and IFN-
induced NF-B-, AP-1-, and C/EBP-dependent luciferase ac-
tivities by 3–5-fold and that of the GAS-dependent one by about
10-fold within 6 h of incubation. However, ISRE-dependent
luciferase activity was not induced in the presence of same
cytokines under the same condition (Fig. 9E). The combination
of IL-1 and IFN- was also unable to induce the activation of
ISRE within 12 or 18 h of incubation (data not shown). Gem-
fibrozil itself did not induce the activation of any of these
transcription factors (Fig. 9). However, this fibrate drug mark-
edly inhibited cytokine-induced activation of NF-B, AP-1, and
C/EBP (Fig. 9, A–C). This inhibitory effect was dose-depend-
ent, and the maximum inhibition was found at 150–200 M
concentration of gemfibrozil. However, activation of C/EBP
was much more sensitive than that of NF-B and AP-1 to
gemfibrozil (Fig. 9). In contrast, gemfibrozil had no inhibitory
effect on GAS-dependent luciferase activities in cytokine-stim-
ulated U373MG astroglial cells (Fig. 9D). At 150 or 200 M
gemfibrozil, only 10–12% inhibition of GAS-dependent lucifer-
ase activity was observed. Similar to the effect of hPPAR- on
the inhibitory effect of gemfibrozil on the induction of iNOS,
hPPAR- was also unable to reverse the inhibitory effect of
gemfibrozil on cytokine-induced activation of NF-B, AP-1, and
C/EBP (data not shown).
Effect of Gemfibrozil on Cell Viability—Human U373MG
astrocytoma cells were incubated with different concentrations
(50, 100, 150, and 200 M) of gemfibrozil under serum-free
condition as mentioned above, and their viability was deter-
mined by the MTT assay. Gemfibrozil used at different concen-
trations did not decrease the viability of the cells (data not
shown). Therefore, inhibition of the expression of iNOS by
gemfibrozil was not due to any change in viability of the cells.
DISCUSSION
The signaling events transduced by proinflammatory cyto-
kines for the induction of iNOS are poorly understood. A com-
plete understanding of the cellular signaling mechanisms in-
volved in the induction of iNOS should identify novel targets
for the therapeutic intervention in NO-mediated neuroinflam-
matory diseases. The studies reported in this manuscript
clearly demonstrates that gemfibrozil, an activator of PPAR-,
reduces the induction of iNOS in human astrocytes. Since
astrocytes express PPAR- (35), and NO produced from iNOS
has been implicated in the pathogenesis of demyelinating and
neurodegenerative diseases (5–7), our results provide a poten-
tially important mechanism whereby activators of PPAR-
may ameliorate neural injury. However, gemfibrozil inhibits
the induction of iNOS in human astroglial cells independent of
PPAR-. This conclusion is based on the following observa-
tions. First, gemfibrozil induced PPRE-dependent luciferase
activity, suggesting that gemfibrozil can activate PPAR in hu-
man astroglial cells. Second, gemfibrozil inhibited cytokine-
induced activation of iNOS promoter suggesting that gemfibro-
zil inhibits the transcription of iNOS. Third, the expression of
hPPAR-, a dominant-negative mutant of human PPAR-,
blocked gemfibrozil-mediated activation of PPRE suggesting
FIG. 8. C/EBP inhibits iNOS promoter-driven luciferase ac-
tivity in cytokine-stimulated human U373MG astroglial cells.
Cells were cotransfected with 0.5 g of either C/EBP or an empty
vector, 0.5 g of phiNOS(7.2)Luc, and 50 ng of pRL-TK. Twenty-four
hours after transfection, cells were stimulated with the combination of
IL-1 and IFN-. After 12 h of incubation, firefly (ff-Luc) and Renilla
(r-Luc) luciferase activities were assayed. Data are mean  S.D. of
three different experiments. *, p  0.005 versus cytokine treatment of
empty vector-transfected cells.
FIG. 9. Effect of gemfibrozil on NF-B- (A), AP-1- (B), C/EBP-
(C), GAS- (D) and ISRE (E)-dependent luciferase activities in
cytokine-stimulated human U373MG astroglial cells. Cells plated
at 50–60% confluence in six-well plates were cotransfected with 1 g of
either pNF-B-Luc, pAP-1-Luc, pC/EBP-Luc, pGAS-Luc, or pISRE-
Luc and 50 ng of pRL-TK. After 24 h of transfection, cells were incu-
bated with different concentrations of gemfibrozil for 2 h and then
stimulated with the combination of IL-1 and IFN- for 6 h under
serum-free condition. Firefly (ff-Luc) and Renilla (r-Luc) luciferase ac-
tivities were obtained by analyzing the total cell extract. Data are
mean  S.D. of three different experiments.
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that gemfibrozil activates PPRE through PPAR-. Fourth,
hPPAR- was unable to block the inhibitory effect of gemfi-
brozil on the induction of iNOS promoter activation, suggesting
that gemfibrozil does not require PPAR- to inhibit the induc-
tion of iNOS in human astroglial cells.
In contrast to the marked induction of iNOS mRNA by the
cytokine combination (Fig. 2), there was only a 3.9-fold induc-
tion of human iNOS promoter in human astroglial cells (Fig. 5),
suggesting that in addition to transcriptional mechanisms
posttranscriptional events could also play a significant role in
regulating the expression of iNOS gene. Several authors have
performed nuclear run-on assays to analyze the induction rate
of the human iNOS promoter in different human cell lines (30,
36–38). These authors have shown that the endogenous iNOS
promoter displays a significant basal activity and that the
induction rate of only 2–10-fold by cytokines is much lower as
seen for the induction of the iNOS mRNA expression. Taken
together, these results suggest that human iNOS gene is reg-
ulated at the level of transcription as well as posttranscription.
However, in our experiment, gemfibrozil does not alter the
relative rate of degradation of human iNOS mRNA in astroglial
cells (Fig. 3), suggesting that gemfibrozil may not couple to
posttranscriptional pathways required for the regulation of
iNOS expression and that gemfibrozil inhibits the expression of
iNOS mRNA mainly at the level of transcription.
Proinflammatory cytokines (TNF-, IL-1, or IFN-) bind to
their respective receptors and induce iNOS expression via ac-
tivation of NF-B (2–4, 22, 26–28). The presence of multiple
consensus sequences in the promoter region of iNOS for the
binding of NF-B and the inhibition of iNOS expression with
the inhibition of NF-B activation (2–4, 22, 26–28) establishes
an essential role of NF-B activation in the induction of iNOS.
Although TNF- or IL-1 alone is capable of inducing the
activation of NF-B, these cytokines alone were not sufficient
to induce the expression of iNOS in human cell lines (39). The
fact that a combination of cytokines is required to induce the
expression of iNOS suggests that activation of additional tran-
scription factors is also necessary for the expression of iNOS.
Consistently, apart from the consensus sequence for binding of
NF-B, the human iNOS promoter contains consensus se-
quences for the binding of transcription factors including AP-1,
C/EBP, IRF-1 binding to ISRE, and STAT binding to GAS
(29–31). The bulk of the work regarding the involvement of
these transcription factors in the transcriptional regulation of
the iNOS gene involved the murine system.
Although the role of these transcription factors in the tran-
scription of human iNOS has not been well established, several
evidences point to their possible involvement in the induction
of iNOS in human cells. Kleinert et al. (32) have shown that the
cytokine mixture induces the tyrosine phosphorylation of
JAK-2 in human DLD-1 cells. This activated JAK-2 further
induces the DNA binding activity of STAT1 (32). Tyrophostin
B42, a specific inhibitor of JAK-2 (33), inhibits the phosphoryl-
ation of JAK-2, the activation of STAT1, and the induction of
iNOS (32), suggesting that the JAK-2-STAT1 pathway is an
important activator of iNOS transcription. Moss and colleagues
(29) have recently shown that activation of both NF-B and
AP-1 is an important step for the transcription of iNOS in
human cells. Mutation in NF-B- as well as AP-1-binding site
of the iNOS promoter reduces the transcriptional activity of
iNOS promoter (29). Furthermore, they (29) have shown that
MAP kinase pathways (ERK and p38) regulate the expression
of iNOS in human lung epithelial (A549) cells through the
modulation of NF-B and AP-1. Recently, we have found that
activation of C/EBP is also necessary for the induction of
iNOS (4). Overexpression of C/EBP, a truncated alternate
C/EBP translational product, LIP, which acts as a dominant-
negative inhibitor of C/EBP activity (34), inhibits the produc-
tion of NO and the expression of iNOS in mouse microglial cells
(4). Consistently, here we show that C/EBP also inhibits
cytokine-induced activation of iNOS promoter in human astro-
glial cells (Fig. 8).
Here we have found that the combination of IL-1 and IFN-
markedly induced the activation of NF-B, AP-1, C/EBP, and
GAS but not that of ISRE in human U373MG astroglial cells.
Interestingly, gemfibrozil suppressed cytokine-induced activa-
tion of NF-B, AP-1, and C/EBP but not that of GAS. Since
STAT binds to GAS (40) and JAK is known to phosphorylate
and activate STAT (40), our results suggest that gemfibrozil
may not inhibit the JAK-STAT pathway in human astrocytes.
On the other hand, IRF-1 binds to ISRE (41). IRF-1 has been
found to be involved in the induction of iNOS by IFN- in
mouse macrophages (42). Consistently, IFN- cannot induce
iNOS in macrophages isolated from IRF-1(/) mice (43). Al-
though the promoter of human iNOS gene contains ISRE (30,
31, 44), the combination of IL-1 and IFN- did not modulate
the activation of ISRE in any significant way, suggesting that
IRF-1 is unlikely to act as an important regulator of cytokine-
induced expression of iNOS in human astrocytes.
Fibrate drugs like gemfibrozil, clofibrate, and fenofibrate
induce the proliferation of peroxisomes in rats and mice (45,
46). Continuous administration of fibrate drugs to the rats and
mice for 40–50 weeks also leads to the formation of hepatic
tumor (45–47). However, induction of hepatic tumor promotion
by fibrate drugs has not been demonstrated in human, other
primates, and guinea pig (46, 48), species that have lost their
ability to synthesize ascorbate due to inherent loss of the gu-
lonolactone oxidase gene. Braun et al. (48) have recently re-
ported that the evolutionary loss of the gulonolactone oxidase
gene may contribute to the missing carcinogenic effect of per-
oxisome proliferators in humans, since ascorbate synthesis is
accompanied by H2O2 production, and consequently its induc-
tion can be potentially harmful. Furthermore, recent studies
have also revealed that humans have considerably lower levels
of PPAR- in liver than rodents, and this difference may, in
part, explain the species differences in the carcinogenic re-
sponse to peroxisome proliferators (46). In addition, gemfibrozil
does not require PPAR- to inhibit the activation of proinflam-
matory transcription factors and the induction of iNOS in hu-
man astroglial cells. Taken together, these observations sug-
gest that gemfibrozil as an anti-neuroinflammatory drug may
not cause human health problems.
NO, a short-lived and diffusible free radical, plays many
roles as a signaling and effector molecule in diverse biological
systems; it is a neuronal messenger and is involved in vasodi-
lation as well as in antimicrobial and antitumor activities (49).
On the other hand, NO has also been implicated in several CNS
disorders, including inflammatory, infectious, traumatic, and
degenerative diseases (5–8, 50). There is considerable evidence
for the transcriptional induction of iNOS (the high output
isoform of NOS) in the CNS that is associated with autoim-
mune reactions, acute infection, and traumatic brain injury
(5–8, 50). Once NO is formed, it spontaneously reacts with O2

to form peroxynitrite (ONOO), the most reactive derivative of
NO known so far (51). Both NO and peroxynitrite are poten-
tially toxic molecules to neurons and oligodendrocytes that may
mediate toxicity through the formation of iron-NO complexes of
iron-containing enzyme systems (52), oxidation of protein sulf-
hydryl groups (51), nitration of proteins, and nitrosylation of
nucleic acids and DNA strand breaks (53).
In the CNS, iNOS is expressed mainly by activated astro-
cytes and microglia, the two glial cell types involved in intrac-
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erebral immune regulation. Astrocytes are the major glial cell
population in the central nervous system; therefore, induction
of iNOS in astrocytes may be an important source of NO in
CNS inflammatory disorders associated with neuronal and oli-
godendrocytes death. Therefore, gemfibrozil being capable of
attenuating the activation of proinflammatory transcription
factors and the expression of iNOS in human astrocytes may
find therapeutic application in neuroinflammatory and neuro-
degenerative disorders.
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